<DOC>
	<DOC>NCT00574743</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of EC-MPS (ERL080) in comparison to MMF in de novo heart recipients.</brief_summary>
	<brief_title>Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criteria Male or female cardiac patients 1865 years old undergoing primary heart transplantation treated with CSME and corticosteroids as basic immunosuppression. Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment. Effective contraception must be used during the trial and for 6 weeks following discontinuation of the study medication, even where there has been a history of infertility. Patients who are willing and able to participate in the full course of the study and from whom written informed consent has been obtained. Exclusion criteria Patients with donor hearts greater than 60 years of age and/or with cold ischemia time of more than 6 hours and/or donor hearts which have obvious coronary disease or are known to have heart disease at time of transplant. Patients on Left Ventricular Assist Device who have received any immunotherapy prior to transplantation or who are scheduled to receive immunotherapy thereafter. Patients with Panel Reactive Antibodies (PRA) 25%. Patients with serum creatinine 3.0mg/dL.. Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception. Patients with a history of significant coagulopathy or medical condition requiring long term anticoagulation after transplantation (low aspirin treatment is allowed). Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>ERL080A, Heart Transplantation, Mycophenolate, EC-MPS</keyword>
</DOC>